A PATH BREAKING THERAPY TO TREAT RHEUMATOID ARTHRITIS

 

COMPOSITION

Tofacitinib 5mg

INDICATIONS

  • RHEUMATOID ARTHRITIS
  • JOINT PAIN
  • JOINT DAMAGE
  • JOINT SWELLING

Rheufa-5

  • A novel disease-modifying antirheumatic drug that helps in the treatment and management of theumatoid arthritis.
  • It is non-inferior to adalimumab in terms of efficacy
  • Excellent anti-inflammatory and analgesic, helps to decrease pain, swelling and tenderness in joints
  • It also significantly improves physical function and stops further arthritis progression.
  • A highly efficacious drug, its efficacy has been confirmed in several clinical trials and it also stops radiographic progression.
  • Possesses an outstanding consistent safety profile, and safety data based on research for 9.5 yrs of research supports this conclusion.
  • Tofacitinib monotherapy is superior to methotrexate in reducing signs and inhibiting the progression of structural joint damage
  • It can induce greater improvements during the first 12-month treatment in DMARD (Disease-modifying antirheumatic drugs) naive patients in comparison with tocilizumab